Effect of feeding method on intake and behaviour of individually reared beef heifers fed a concentrate diet from 115 to 185 kg of body weight

A total of eight Simmental heifers (114 ± 3.2 days old and weighing 118 ± 3.8 kg BW) were used to study the effects of feeding method on intake and animal behaviour in a crossover design experiment. Treatments consisted of feeding concentrate and chopped barley straw as (1) choice (CH; concentrate and straw in separate feedbunks) or (2) total mixed ration (TMR; concentrate and straw in one feedbunk). Feeds were offered on an ad libitum basis, but always maintaining a concentrate to straw ratio of 90 to 10. The experiment was performed in two 21-day periods, and sampling was carried out in the last week of each period. At the end of each period, treatment was changed for heifers; hence, the final number of animals per treatment was eight. Intake was recorded over 7 consecutive days. BW was recorded at the beginning and the end of the experiment and on day 21 of each experimental period. Barley straw was coarsely chopped with a chopping machine. Once chopped, all the straw was handled for particle size separation using the 2-screen Penn State Particle Separator and only material of more than 8 mm was used to feed the heifers. Animal behaviour was video-recorded for 24 h on day 2 and day 6 of each experimental period. Concentrate intake and total dry matter intake of heifers fed with the CH feeding method were higher (P < 0.01 and P < 0.05) than when fed with TMR (5.1 and 5.3 v. 4.7 and 5.0 kg dry matter (DM)/day, respectively). Conversely, barley straw was consumed in higher amounts in heifers fed with the TMR feeding method (0.3 v. 0.2 kg DM/day, respectively; P = 0.001). The total NDF intake was similar in both treatments. In contrast, NDF intake from barley straw and physically effective NDF intake were higher in heifers fed with the TMR feeding method than when fed with CH. Feeding method used to feed heifers did not affect the consumption of the different kinds of barley straw particles and eating and drinking behaviours but affected ruminating behaviour. Heifers fed TMR spent more time ruminating than heifers fed concentrate and barley straw separately (376 v. 287 min/day, respectively; P < 0.01). TMR as the feeding method in intensive beef production systems could be a good approach to promote roughage intake

Discovering HIV related information by means of association rules and machine learning

Acquired immunodeficiency syndrome (AIDS) is still one of the main health problems worldwide. It is therefore essential to keep making progress in improving the prognosis and quality of life of affected patients. One way to advance along this pathway is to uncover connections between other disorders associated with HIV/AIDS-so that they can be anticipated and possibly mitigated. We propose to achieve this by using Association Rules (ARs). They allow us to represent the dependencies between a number of diseases and other specific diseases. However, classical techniques systematically generate every AR meeting some minimal conditions on data frequency, hence generating a vast amount of uninteresting ARs, which need to be filtered out. The lack of manually annotated ARs has favored unsupervised filtering, even though they produce limited results. In this paper, we propose a semi-supervised system, able to identify relevant ARs among HIV-related diseases with a minimal amount of annotated training data. Our system has been able to extract a good number of relationships between HIV-related diseases that have been previously detected in the literature but are scattered and are often little known. Furthermore, a number of plausible new relationships have shown up which deserve further investigation by qualified medical experts

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI) : a phase 3, placebo-controlled, randomised trial

Background: Patients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic events. These patients are generally treated with aspirin. In this trial, we aimed to investigate if these patients would benefit from treatment with aspirin plus ticagrelor. Methods: The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) was a phase 3 randomised, double-blinded, placebo-controlled trial, done in 1315 sites in 42 countries. Patients were eligible if 50 years or older, with type 2 diabetes, receiving anti-hyperglycaemic drugs for at least 6 months, with stable coronary artery disease, and one of three other mutually non-exclusive criteria: a history of previous PCI or of coronary artery bypass grafting, or documentation of angiographic stenosis of 50% or more in at least one coronary artery. Eligible patients were randomly assigned (1:1) to either ticagrelor or placebo, by use of an interactive voice-response or web-response system. The THEMIS-PCI trial comprised a prespecified subgroup of patients with previous PCI. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke (measured in the intention-to-treat population). Findings: Between Feb 17, 2014, and May 24, 2016, 11 154 patients (58% of the overall THEMIS trial) with a history of previous PCI were enrolled in the THEMIS-PCI trial. Median follow-up was 3·3 years (IQR 2·8–3·8). In the previous PCI group, fewer patients receiving ticagrelor had a primary efficacy outcome event than in the placebo group (404 [7·3%] of 5558 vs 480 [8·6%] of 5596; HR 0·85 [95% CI 0·74–0·97], p=0·013). The same effect was not observed in patients without PCI (p=0·76, p interaction=0·16). The proportion of patients with cardiovascular death was similar in both treatment groups (174 [3·1%] with ticagrelor vs 183 (3·3%) with placebo; HR 0·96 [95% CI 0·78–1·18], p=0·68), as well as all-cause death (282 [5·1%] vs 323 [5·8%]; 0·88 [0·75–1·03], p=0·11). TIMI major bleeding occurred in 111 (2·0%) of 5536 patients receiving ticagrelor and 62 (1·1%) of 5564 patients receiving placebo (HR 2·03 [95% CI 1·48–2·76], p<0·0001), and fatal bleeding in 6 (0·1%) of 5536 patients with ticagrelor and 6 (0·1%) of 5564 with placebo (1·13 [0·36–3·50], p=0·83). Intracranial haemorrhage occurred in 33 (0·6%) and 31 (0·6%) patients (1·21 [0·74–1·97], p=0·45). Ticagrelor improved net clinical benefit: 519/5558 (9·3%) versus 617/5596 (11·0%), HR=0·85, 95% CI 0·75–0·95, p=0·005, in contrast to patients without PCI where it did not, p interaction=0·012. Benefit was present irrespective of time from most recent PCI. Interpretation: In patients with diabetes, stable coronary artery disease, and previous PCI, ticagrelor added to aspirin reduced cardiovascular death, myocardial infarction, and stroke, although with increased major bleeding. In that large, easily identified population, ticagrelor provided a favourable net clinical benefit (more than in patients without history of PCI). This effect shows that long-term therapy with ticagrelor in addition to aspirin should be considered in patients with diabetes and a history of PCI who have tolerated antiplatelet therapy, have high ischaemic risk, and low bleeding risk